In 1996, researchers from Genentech (San Francisco, CA, USA) engineered actin-resistant DNase1 variants which reduced the viscoelasticity of CF patient sputum 10- to 50-fold more potently than native DNase1 (41). Here, DNASE1 is linked to cystic fibrosis.